Oxford Asset Management LLP Acquires Shares of 17,134 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Oxford Asset Management LLP acquired a new stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 17,134 shares of the company’s stock, valued at approximately $52,000.

A number of other institutional investors also recently added to or reduced their stakes in ZNTL. Barclays PLC boosted its holdings in Zentalis Pharmaceuticals by 18.5% in the 3rd quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after purchasing an additional 11,748 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Zentalis Pharmaceuticals by 115.6% in the 4th quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock valued at $171,000 after purchasing an additional 30,240 shares in the last quarter. Savant Capital LLC purchased a new stake in Zentalis Pharmaceuticals in the 4th quarter valued at approximately $72,000. Ieq Capital LLC purchased a new stake in Zentalis Pharmaceuticals in the 4th quarter valued at approximately $46,000. Finally, Anfield Capital Management LLC boosted its holdings in Zentalis Pharmaceuticals by 100.0% in the 4th quarter. Anfield Capital Management LLC now owns 129,318 shares of the company’s stock valued at $392,000 after purchasing an additional 64,659 shares in the last quarter.

Zentalis Pharmaceuticals Stock Down 0.7 %

ZNTL opened at $1.42 on Tuesday. The firm has a market cap of $101.97 million, a P/E ratio of -0.57 and a beta of 1.80. Zentalis Pharmaceuticals, Inc. has a 52 week low of $1.01 and a 52 week high of $13.24. The business’s fifty day simple moving average is $1.64 and its 200 day simple moving average is $2.49.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09. The company had revenue of $26.90 million for the quarter. As a group, equities analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Insider Activity at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, insider Ingmar Bruns purchased 20,000 shares of the firm’s stock in a transaction on Thursday, February 6th. The shares were purchased at an average cost of $2.28 per share, with a total value of $45,600.00. Following the purchase, the insider now owns 36,629 shares in the company, valued at approximately $83,514.12. This represents a 120.27 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Jan Skvarka purchased 60,000 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was acquired at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the purchase, the director now owns 149,551 shares in the company, valued at $257,227.72. The trade was a 67.00 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Wells Fargo & Company decreased their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday, March 27th. Wedbush restated a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, March 28th. Finally, UBS Group dropped their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.